Houston (1)

Blasts More Than 20 Percent of Bone Marrow Nucleated Cells (1)

Blasts More Than 20 Percent of Peripheral Blood White Cells (1)

Myelodysplastic/Myeloproliferative Neoplasm (1)

Recurrent Acute Myeloid Leukemia (1)

Refractory Acute Myeloid Leukemia (1)

Completed (1)

phase 1/phase 2 (1)

M.D. Anderson Cancer Center (1)

National Cancer Institute (NCI) (1)

decitabine (1)

laboratory biomarker analysis (1)

ruxolitinib phosphate (1)

drug (1)

other (1)

Other (1)

Interventional (1)

blasts more than 20 percent of peripheral blood white cells

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Completed

Jul 18, 2022